Lancet Diabetes & Endocrinology

Article	Citations
Direct-to-consumer services: improving access to care for people with diabetes and obesity	1198
Long-term trial outcomes of Roux-en-Y gastric bypass and one anastomosis gastric bypass: tipping the scale	985
South Africa to produce insulin for Africa in 2024	655
Reassessing driving safety in diabetes	605
Better testing and labelling of drugs for people with obesity	604
Anand Hardikar: a scientific nomad searching for the truth	442
What's preventing us from curbing the obesity crisis?	287
A framework for improving diabetes care in humanitarian emergencies	275
Artificial intelligence and diabetes: time for action and caution	254
Correction to Lancet Diabetes Endocrinol 2022; published online Sept 29. https://doi.org/10.1016/S2213-8587(22)00252-2	248
Correction to Lancet Diabetes Endocrinol 2022; 10: 489–98	240
Specific cortisol blockade in Cushing's syndrome	229
Estimating direct tissue effects versus weight loss effects of incretin-based drugs for obesity on various chronic conditions	225
Type 1 diabetes screening: need for ethical, equity, and health systems perspective	208
Effect of sodium–glucose co-transporter-2 inhibitors on survival free of organ support in patients hospitalised for COVID-19 (ACTIV-4a): a pragmatic, multicentre, open-label, randomised, controlled, p	199
Artificial intelligence for interpreting diabetes data using clinician-curated benchmarks	198
Comparison of incidence patterns and risk profiles of ST-elevation and non-ST-elevation myocardial infarction in type 1 diabetes in Finland: a nationwide cohort study	195
World Health Assembly ratifies first global diabetes targets	191
Metastases to the thyroid gland: how does this affect cytohistological diagnoses?	182
Outcomes in children of women with type 2 diabetes exposed to metformin versus placebo during pregnancy (MiTy Kids): a 24-month follow-up of the MiTy randomised controlled trial	182
Association of glycaemic index and glycaemic load with type 2 diabetes, cardiovascular disease, cancer, and all-cause mortality	174
International Federation for the Surgery of Obesity statement on metabolic bariatric surgery after pharmacotherapy-induced weight loss in clinical obesity	173
Clinical features, investigation, and management of Addison's disease	170
Implications of technology guidelines for low-income and middle-income countries	167
Effect of sotagliflozin on major adverse cardiovascular events: a prespecified secondary analysis of the SCORED randomised trial	162

Long-term effects and effect heterogeneity of lifestyle and metformin interventions on type 2 diabetes incidence over 21 years in the US Diabetes Prevention Program randomised clinical trial	137
Multiple endocrine neoplasia type 1 (MEN1): recommendations and guidelines for best practice	136
What does renal failure teach us about our National Health System?	135
Challenging diabetes stigma starts and ends with all of us	130
Glycaemic index as part of the diabetes prevention strategy	125
The role of nurses in diabetes care: challenges and opportunities	124
A roadmap for integrating mental health and diabetes services	122
Cardiovascular mortality trends among people with and without diabetes	122
The Human Insulin Thermal Solution project—a private sector initiative to address the thermostability of insulin	115
Healthy weight for the next generation's health in China	115
The promise and hope of GLP-1 receptor agonists	113
The urgent need for a diabetes data rights charter	113
The uncomfortable truth about kidney disease in type 1 diabetes	108
Glucose-lowering drugs with cardiovascular benefits as modifiers of critical elements of the human life history	107
Retraction and republication—Estimating dose-response relationships for vitamin D with coronary heart disease, stroke, and all-cause mortality: observational and Mendelian randomisation analyses	103
Application of continuous glucose monitoring and automated insulin delivery technologies for pregnant women with type 1, type 2, or gestational diabetes: an international consensus statement	103
Behind the scenes: epigenetic mechanisms rule the roost in pubertal timing	102
Comparing the effectiveness of glucose-lowering agents: real-world data to emulate a four-arm target trial – Authors' reply	102
Putting wellbeing at the core of diabetes care	101
Adjuvant mitotane versus surveillance in low-grade, localised adrenocortical carcinoma (ADIUVO): an international, multicentre, open-label, randomised, phase 3 trial and observational study	99
Sodium–glucose co-transporter-2 inhibitors for hospitalised patients with COVID-19: a prospective meta-analysis of randomised trials	98
Correction to Lancet Diabetes Endocrinol 2025; 13: 935–48	96
Association of glycaemic index and glycaemic load with type 2 diabetes in the PURE study	96
Are we closer to surpassing residual renal risk in type 2 diabetes?	95
Diabetes and mental health	93
Explaining the high rate of progression from prediabetes to type 2 diabetes in China	92
Correction to Lancet Diabetes Endocrinol 2025; published online April 7. https://doi.org/10.1016/S2213-8587(25)00087-7	90
Correction to Lancet Diabetes Endocrinol 2025; published online Nov 19. https://doi.org/10.1016/S2213-8587(25)00289-X	89
Trajectories of type 2 diabetes and cancer in 330 000 individuals with prediabetes: 20-year observational study in England	88
Hyperthyroidism: aetiology, pathogenesis, diagnosis, management, complications, and prognosis	87
Efficacy and safety of tirzepatide added to basal insulin in patients with type 2 diabetes in China (SURPASS-CN-INS): a double-blind, multicentre, randomised, placebo-controlled, phase 3 trial	83
3 months vs 12 months of romosozumab for postmenopausal osteoporosis (LIDA): an open-label, non-inferiority, randomised controlled trial	81
Understanding the mechanism of prediabetes remission in young people	80
CONCEPTT to care: the science of implementation in diabetes care	80
The long and winding road to precision diabetology	79
Correction to Lancet Diabetes Endocrinol 2022; 10: 407–17	78
Bothersome vasomotor symptoms: a potential early clinical marker of perimenopause?	78
Efficacy and safety of dapagliflozin in patients with heart failure with mildly reduced or preserved ejection fraction by baseline glycaemic status (DELIVER): a subgroup analysis from an international	78
Blood pressure control according to type 2 diabetes status	77
Correction to Lancet Diabetes Endocrinol 2022; 10: 481–83	76
Correction to Lancet Diabetes Endocrinol 2023; 11: 402–13	75
Diabetes: knowing your risk matters	75
Gender equality: timely and timeless	74
Balancing hormonal shifts: exploring the impact of ageing and dietary restriction	73
Improving HbA1c levels with advanced hybrid closed-loop therapy	71
Aberrant hormone receptors regulate a wide spectrum of endocrine tumors	70
Is it time to re-assess the development of thyroid function reference ranges?	70
Glucagon, from past to present: a century of intensive research and controversies	69
GLP-1 receptor agonists for obesity: eligibility across 99 countries	69
A novel diagnostic score for diagnosing arginine vasopressin deficiency (central diabetes insipidus) or primary polydipsia with basal laboratory and clinical parameters: results from two international	68

Staging prediabetes and type 2 diabetes: the time to start is now	67
Association of glycaemic index and glycaemic load with type 2 diabetes, cardiovascular disease, cancer, and all-cause mortality: a meta-analysis of mega cohorts of more than 100 000 participants	64
Hypothalamic obesity: from basic mechanisms to clinical perspectives	63
Rare variants in the MECP2 gene in girls with central precocious puberty: a translational cohort study	61
On the occasion of International Women's Day	60
Male hypogonadism: pathogenesis, diagnosis, and management	60
Chronicling insulin from discovery to crisis	59
Central diabetes insipidus from a patient's perspective	58
Improving support for university students with type 1 diabetes	57
Embracing multiplicity in global diabetes estimation methods	56
Diagnosing diabetes in African populations: a twist in the tale	56
Sleep your way to better metabolic health	55
USP8 genotype and tumour size as predictors for recurrence in Cushing's disease	55
Vitamin D and fractures	55
Mendelian randomisation and vitamin D: the importance of model assumptions – Authors' reply	54
TB Joshua and his megachurch: fake medical miracles and abuse in Nigeria	54
World Autism Awareness Day: autism and metabolic health	53
Teplizumab approval for type 1 diabetes in the USA	52
Has the WHO Model Essential Medicines List lost its way?	52
Vitamin D supplementation to prevent acute respiratory infections: systematic review and meta-analysis of stratified aggregate data	51
Efficacy and safety of automated insulin delivery in children aged 2–6 years (LENNY): an open-label, multicentre, randomised, crossover trial	51
Is weight cycling clinically harmful?	51
GLP-1 receptor agonists in kidney transplant recipients with pre-existing diabetes: a retrospective cohort study	51
Embracing community sport to promote global health	51
Autologous and allogeneic stem cell-derived islet therapy in three recipients with type 1 diabetes and complete loss of endogenous pancreatic β-cell function pretransplant	50
Management of menopause: a view towards prevention	50
Continuous glucose monitoring versus blood glucose monitoring for risk of severe hypoglycaemia and diabetic ketoacidosis in children, adolescents, and young adults with type 1 diabetes: a population-b	50
Switching to once-weekly insulin icodec versus once-daily insulin degludec in individuals with basal insulin-treated type 2 diabetes (ONWARDS 2): a phase 3a, randomised, open label, multicentre, treat	49
Effect of surgical versus conservative management on cardiovascular outcomes in patients with bilateral adrenal tumours and cortisol excess: an international, retrospective cohort study	49
Screening type 1 diabetes and celiac disease by law	49
Insulin regimens during type 1 diabetes pregnancy	48
Automated insulin delivery postpartum: insights from the AiDAPT study extension	48
Young adult-onset type 2 diabetes heralds a poor prognosis	48
Correction to Lancet Diabetes Endocrinol 2025; 13: 909–10	47
Technology for type 1 diabetes: what impact will it have?	46
Decision making in differences of sex development/intersex care in the USA: bridging advocacy and family-centred care	46
More options for young children with type 1 diabetes	46
Combined associations of GLP-1 receptor agonists and a healthy lifestyle with cardiovascular outcomes among individuals with type 2 diabetes: a prospective cohort study	45
Correction to Lancet Diabetes Endocrinol 2024; 12: 233–46	45
Does siRNA therapy against ANGPTL3 bring new hope in homozygous familial hypercholesterolaemia?	45
Blood glucose targets in the critically ill: is one size fits all still appropriate?	45
Achievement of guideline recommended diabetes treatment targets and health habits in people with self-reported diabetes in India (ICMR-INDIAB-13): a national cross-sectional study	44
Impact of the COVID-19 pandemic on long-term trends in the prevalence of diabetic ketoacidosis at diagnosis of paediatric type 1 diabetes: an international multicentre study based on data from 13 nati	44
11th edition of the IDF Diabetes Atlas: global, regional, and national diabetes prevalence estimates for 2024 and projections for 2050	44
Correction to Lancet Diabetes Endocrinol 2022; 10: 668–80	44
Explaining the high rate of progression from prediabetes to type 2 diabetes in China – Authors' reply	43
MarÍa José Redondo: rethinking type 1 diabetes	43
An inclusive approach to people with disabilities in diabetes care and education	43
ORION-3: delivering lipid lowering treatment for longer	43
Thank you to The Lancet Diabetes & Endocrinology's statistical and peer reviewers in 2023	42
Diabetes and cancer in the age of multimorbidity	42
Addressing health and demographic challenges in Japan's ageing society	41
Causal inference in perinatal epidemiology: big data's false promises	41
How clinically relevant is statin-induced diabetes?	41
Life stage transitions for people with type 1 diabetes	40
Analogue insulin, GLP-1, and the WHO Model Essential Medicines List	39
Disparities in fragility fracture and osteoporosis care in Africa	39
Enhancing global access to diabetes medicines: policy lessons from the HIV response	39
From reproduction to metabolism: FSH as a key modulator in menopause	38
Correction to Lancet Diabetes Endocrinol 2024; 12: 39–50	38
Burden of diabetes and hyperglycaemia in adults in the Americas, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019	38
Associations between BMI and hospital resource use in patients hospitalised for COVID-19 in England: a community-based cohort study	37
Efficacy and safety of bempedoic acid among patients with and without diabetes: prespecified analysis of the CLEAR Outcomes randomised trial	37
Oxytocin in response to MDMA provocation test in patients with arginine vasopressin deficiency (central diabetes insipidus): a single-centre, case-control study with nested, randomised, double-blind,	37
Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial	36
Impact of higher BMI on cardiometabolic risk: does height matter?	35
Rethinking prophylactic central neck dissection in clinically node-negative papillary thyroid cancer	35
Implications of microplastics as emerging endocrine disruptors	35
Once-weekly semaglutide in people with HIV-associated lipohypertrophy: a randomised, double-blind, placebo-controlled phase 2b single-centre clinical trial	35
Type 1 diabetes in diverse ancestries and the use of genetic risk scores	34
Redefining obesity: advancing care for better lives	34
Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial	34
Disease modifying therapies in diabetes and endocrinology	33
Setmelanotide: new promise for the treatment of hypothalamic obesity?	32
Incretins and the cardiovascular system: bridging digestion with metabolism	32
Task shifting and task sharing in paediatric type 1 diabetes care: a global survey	32
Pharmacogenomics of GLP-1 receptor agonists: a genome-wide analysis of observational data and large randomised controlled trials	31
Sleep: a neglected public health issue	31
Effects of empagliflozin on conventional and exploratory acute and chronic kidney outcomes: an individual participant-level meta-analysis	30
Effect of gastric bypass versus sleeve gastrectomy on the remission of type 2 diabetes, weight loss, and cardiovascular risk factors at 5 years (Oseberg): secondary outcomes of a single-centre, triple	30

Mendelian randomisation and vitamin D: the importance of model assumptions	29
From prominent corneal nerves to multiple endocrine neoplasia type 2B	29
Improving type 1 diabetes care globally: the importance of medical education	29
Iodine deficiency in Europe: vigilance and action required	29
Perfluoroalkyl and polyfluoroalkyl substances: the price of forever chemicals	29
What's in a decade?	29
The growing global burden of thyroid cancer overdiagnosis	28
The evolutionary basis for type 2 diabetes prevalence in the Arabian Peninsula	28
The potential role for artificial intelligence in fracture risk prediction	28
Correction to Lancet Diabetes Endocrinol 2022; 10: 741–60	28
Effect of the COVID-19 pandemic on surgery for indeterminate thyroid nodules (THYCOVID): a retrospective, international, multicentre, cross-sectional study	28
Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel	27
Correction to Lancet Diabetes Endocrinol 2026; 14: 317–26	27
Sex differences in familial hypercholesterolaemia	26
Multi-ancestry polygenic risk scores for the prediction of type 2 diabetes and complications in diverse ancestries	25
Heterogeneity in type 2 diabetes trajectories: informing public health approaches	25
Maternal thyroid hypofunction and gestational diabetes risk	25
Low visceral fat and kidney disease risk in men with diabetes	25
Correction to Lancet Diabetes & Endocrinology 2026; 14: 105–08	25
The double burden of poor diets	24
A comparison of the effects of tirzepatide and dulaglutide on major kidney events in people with type 2 diabetes: pre-specified exploratory analyses of the SURPASS-CVOT trial	24
Understanding diabetes heterogeneity: key steps towards precision medicine in diabetes	24
Continuous glucose monitoring versus self-monitoring of blood glucose in individuals with type 2 diabetes: a randomised, multicentre, open-label, superiority trial	24
From survival to freedom: redefining success in type 1 diabetes	24
Contribution of heterozygous PCSK1 variants to obesity and implications for precision medicine: a case-control study	24
Prediabetes remission and cardiovascular morbidity and mortality: post-hoc analyses from the Diabetes Prevention Program Outcome study and the DaQing Diabetes Prevention Outcome study	23
Achieving replicable subphenotypes of adult-onset diabetes – Authors' reply	23
From research to policy: still a long way to go	23
Once-weekly semaglutide 7·2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial	23
Bariatric surgery in children with obesity and type 2 diabetes	23
A global plastics treaty to protect endocrine health	23
Managing insulin resistance: the forgotten pathophysiological component of type 2 diabetes	23
Correction to Lancet Diabetes Endocrinol 2024; 12: 39–50	23
Treatments for MEN1-associated endocrine tumours: three systematic reviews and a meta-analysis	23
Long-term sex differences in atherosclerotic cardiovascular disease in individuals with heterozygous familial hypercholesterolaemia in Spain: a study using data from SAFEHEART, a nationwide, multicent	23
Lessons to learn from the 2024 NICE guideline on adrenal insufficiency	22
Peripheral CB1 receptor blockade for treatment of obesity	22
Is biased agonism helpful in the treatment of obesity with the GLP-1 receptor analogues?	22
More liberal use of bilateral adrenalectomy for bilateral adrenal tumours with cortisol excess	22
The impact of the COVID-19 pandemic and associated disruptions in health-care provision on clinical outcomes in people with diabetes: a systematic review	22
Addressing the educational needs of older adults with type 1 diabetes	22
Endocrine health in survivors of adult-onset cancer	22
Reversibility of congenital hypogonadotropic hypogonadism: lessons from a rare disease	21
Efficacy and safety of setmelanotide, a melanocortin-4 receptor agonist, in patients with Bardet-Biedl syndrome and Alström syndrome: a multicentre, randomised, double-blind, placebo-controlled, phase	21
Association between maternal diabetes and neurodevelopmental outcomes in children: a systematic review and meta-analysis of 202 observational studies comprising 56·1 million pregnancies	21
SGLT2 inhibitors and GLP-1 receptor agonists: the definitive combination?	21
Does tirzepatide treatment improve skeletal muscle composition?	20
Continuous glucose monitoring and metrics for clinical trials: an international consensus statement	20
Use of melatonin supplements and risk of type 2 diabetes and cardiovascular diseases in the USA: insights from three prospective cohort studies	20
Comorbidities and mortality in subgroups of adults with diabetes with up to 14 years follow-up: a prospective cohort study in Sweden	20
3 months of romosozumab: a pragmatic clinical solution	20
Correction to Lancet Diabetes Endocrinol 2023; 11: 905–14	19
Good news for patients with adrenocortical carcinoma from the ADIUVO trial	19
Mendelian randomisation at 20 years: how can it avoid hubris, while achieving more?	19
Association between primary graft function and 5-year outcomes of islet allogeneic transplantation in type 1 diabetes: a retrospective, multicentre, observational cohort study in 1210 patients from th	19
The voices of lived experience in diabetes and endocrinology	19
Sugar, sugary drinks, and health: has the evidence achieved the sweet spot for policy action?	19
Analysis of cluster randomised trials as if they were individually randomised – Authors' reply	19
Analogue insulin, GLP-1, and the WHO Model Essential Medicines List	19
Blood pressure reduction and major cardiovascular events in people with and without type 2 diabetes	19
A call for increased involvement of people with obesity and neurodiversity in policy, research, and practice	19
What REDEFINE 5 signals for obesity trials in Asia and beyond	19